Bionano Genomics (BNGO) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Business transformation and strategic focus

• Transitioning to a capital-efficient model, prioritizing recurring revenue from the installed base over global expansion.

• Emphasis on increasing utilization at 91 validated routine-use sites, especially in the U.S., Canada, Europe, and Israel.

• Strategic reduction in operating expenses, including headcount and R&D, to achieve cash flow breakeven within three to four years.

• Refocusing resources away from non-profitable geographies and freezing some R&D projects.

• Revised annual operating expense target to approximately $33.7 million.

Product innovation and market adoption

• Launched the Stratys System, a third-generation platform with four times the throughput of its predecessor.

• VIA software, developed with NVIDIA, streamlines genome analysis and reporting.

• Optical genome mapping consolidates three legacy cytogenetic methods, offering faster and more actionable results at lower cost.

• 360 systems installed globally, with 91 sites in routine use, driving consumables revenue.

• First pediatric hospital adoption and new CPT code in the U.S. accelerating clinical uptake.

Financial performance and guidance

• Trailing twelve months revenue of $36.6 million, up 16% year-over-year; Q2 revenue impacted by discontinued products.

• Installed base expanded by 30% year-over-year; $30 million in cash and equivalents at quarter end.

• Full-year revenue guidance revised to $32–$36 million, with Q3 guidance of $7.9–$8.9 million.

• Focus on improving gross margin through increased volume and reduced manufacturing costs.